The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2017 | Novel agents in multiple myeloma: considering toxicity and side effects

Name: Novel agents in multiple myeloma: considering toxicity and side effects
Uploaded: 2017-06-23T14:31:36.000Z
Duration: 1 min 2 s
Description: We've seen a number of approvals in multiple myeloma over the past year. Enrique M. Ocio, MD, PhD, from the University of Salamanca, Salmanca, Spain discusses the results from recent studies presented at the European Hematology Association (EHA) 2017 meeting, as well as the novel adverse events and toxicities that these new drugs can cause.

Enrique Ocio • 23 Jun 2017

EHA 2017

Multiple Myeloma

We’ve seen a number of approvals in multiple myeloma over the past year. Enrique M. Ocio, MD, PhD, from the University of Salamanca,
Salmanca, Spain discusses the results from recent studies presented at the European Hematology Association (EHA) 2017 meeting, as well as the novel adverse events and toxicities that these new drugs can cause.